1 Copenhagen Trial Unit, Cochranecenteret Rigshospitalet, Rigshospitalet, The Capital Region of Denmark2 Division of Gastroenterology and Rheumatology Department of Internal Medicine, Neurology and Dermatology, University of Leipzig, Liebigstrasse 20, Leipzig, Germany, 04103.3 unknown
Hepatocellular carcinoma is the fifth most common cancer worldwide. Percutaneous interventional therapies, such as radiofrequency (thermal) ablation (RFA), have been developed for early hepatocellular carcinoma. RFA competes with other interventional techniques such as percutaneous ethanol injection, surgical resection, and liver transplantation. The potential benefits and harms of RFA compared with placebo, no intervention, chemotherapy, hepatic resection, liver transplantation, or other interventions are unclear.
Cochrane Database of Systematic Reviews, 2013, Vol 12